Here are relevant reports on : ai-route-planning-market
-
Immunotherapy Drugs Market by Type (mAb, Checkpoint Inhibitor, Interferon, Cancer Vaccine), Application (Cancer, Autoimmune, Inflammatory, Hematology, Neurology), Route of Administration (Intravenous, Subcutaneous), End User - Global Forecast to 2029
The global immunotherapy drugs market, valued at US$255.9 billion in 2023, stood at US$285.3 billion in 2024 and is projected to advance at a resilient CAGR of 15.3% from 2024 to 2029, culminating in a forecasted valuation of US$580.6 billion by the end of the period. This growth is driven by technological advancements in antibody engineering, increasing demand for antibody therapies in clinical cancer treatment, and a growing preference for personalized medicines and targeted therapies.
- Published: July 2024
- Price: $ 4950
- TOC Available:
-
Asia Pacific Pharmaceutical Drug Delivery Market by Route of Administration (Oral, Injectors (Auto Injectors), Implantable, Transmucosal, Nasal, Syringes), Application (Cancer, Diabetes), Care Setting (Hospital, Home Care) - Forecast to 2031
The Asia Pacific pharmaceutical drug delivery market, valued at US$457.9 million in 2025, stood at US$479.7 million in 2026 and is projected to advance at a resilient CAGR of 7.5% from 2026 to 2031, culminating in a forecasted valuation of US$687.9 million by the end of the period. The market growth for drug delivery in the APAC region is steadily expanding due to an increase in disease prevalence, an increase in the adoption rate of biologics, advancements in technologies, and an increase in regional production.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Asia Pacific Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR), Route of Administration (IM, SC, Oral) - Forecast to 2030
The Asia Pacific Vaccines market, valued at USD 9.46 billion in 2024, stood at USD 9.89 billion in 2025 and is projected to advance at a resilient CAGR of 9.0% from 2025 to 2030, culminating in a forecasted valuation of USD14.57 billion by the end of the period. The market is expanding quickly, driven by a rise in vaccine development and commercialization, heightened infectious disease rates, and the extensive use of preventive vaccines.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
US Veterinary Vaccines Market by Type (Porcine, Poultry, Livestock, Companion Animals), Technology (Live Attenuated, Inactivated, Toxoid), Route of Administration (Intramuscular, Subcutaneous, Oral), and End User (Hospitals, Clinics) – Forecast to 2031
The US veterinary vaccines market, valued at USD4.39 billion in 2025, stood at USD4.67 billion in 2026 and is projected to advance at a resilient CAGR of 6.8% from 2026 to 2031, culminating in a forecasted valuation of USD6.50 billion by the end of the period. This growth is attributed to the increasing awareness regarding animal health as well as the rising pet population and pet ownership. Other emerging trends affecting the growth of this segment are government initiatives to improve the health of animals and increased adoption of pet coverage.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Europe Veterinary Vaccines Market by Type (Porcine, Poultry, Livestock, Companion Animals), Technology (Live Attenuated, Inactivated, Toxoid), Route of Administration (Intramuscular, Subcutaneous, Oral), and End User (Hospitals, Clinics) – Forecast to 2031
The Europe veterinary vaccines market, valued at USD3.84 billion in 2025, stood at USD4.08 billion in 2026 and is projected to advance at a resilient CAGR of 6.6% from 2026 to 2031, culminating in a forecasted valuation of USD5.61 billion by the end of the period. The growth of the market is driven by the increased pet ownership and greater emphasis on animal welfare.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Hemophilia Treatment Market by Indication (Type A, Type B), Therapy (Replacement (Recombinant, Plasma Derived), Route of Administration, End User - Global Forecast to 2027
The global hemophilia treatment market is projected to reach USD ~15 billion by 2027 from USD 12 Billion in 2022, at a CAGR of 5% during the forecast period. The major players in the global hemophilia market are Bayer Healthcare (Germany), Octapharma AG (Switzerland), Novo Nordisk (Denmark), Kedrion (Italy), Pfizer Inc. (US), Biogen (US) among others.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Veterinary Pain Management Market by Product (Drug (NSAIDs, Opioids), Route of Administration (Oral, Parenteral), Device (Laser)), Application (Joint Pain, Cancer), Animal (Companion and Livestock), End User (Hospital, Pharmacy) - Global Forecast to 2027
Veterinary pain management market growth is primed to transition from $1.8 billion in 2022 to $2.5 billion by 2027, showcasing a strong CAGR of 6.7%. Factors such as growth in companion animal adoption, the increasing number of veterinary practitioners and their rising income levels in developed economies, increasing consumption of meat & milk, the growing prevalence of animal disease causing pain and inflammation, and rising adoption of pet insurance with growing animal health expenditure are expected to drive the growth of this market.
- Published: September 2022
- Price: $ 4950
- TOC Available:
-
Graph Analytics Market by Component, Deployment Mode, Organization Size, Application (Route Optimization and Fraud Detection), Vertical (Healthcare and Life Sciences, Transportation and Logistics, and BFSI), and Region - Global Forecast to 2024
The global graph analytics market size is expected to grow USD 2,522 million by 2024, at a Compound Annual Growth Rate (CAGR) of 34.0% during the forecast period. Major North American vendors in the graph analytics market are Microsoft (US), IBM (US), AWS (US), Oracle (US), Neo4j (US), TigerGraph (US), Cray (US), DataStax (US), Teradata (US), TIBCO Software (US), Graphistry (US), Objectivity (US), Dataiku (US), Tom Sawyer Software (US), Kineviz (US), Franz (US), and Expero (US).
- Published: October 2019
- Price: $ 4950
- TOC Available:
-
Migraine Drugs Market by Product Type (Acute migraine treatment, Preventive migraine treatment), Route of administration (Oral, Injection, and Others), and End User (Hospital pharmacies, Retail pharmacies, Online pharmacies) - Global Forecast to 2023
The global Migrane Drugs market is expected to reach USD 3.96 billion by 2023 from USD 1.95 million in 2018, growing at a CAGR of 15.2%. Increasing awareness about novel therapies, launch of Calcitonin Gene-related Peptide (CGRP), increasing incidence of migraines and launch of new drugs are some of the major factors driving the growth of the global suture anchor market. These driving factors consequence to the rapid adoption of these new drugs, thus propelling the market growth.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Aviation Analytics Market by Application (Fuel Management, Route Management, Flight Risk Management, inspection, others), End-User (MROs, Airlines, Airports, OEMs), Component, Deployment, Business Function, and - Global Forecast to 2027
The Aviation Analytics market is expected to grow from USD 2.5 billion in 2022 to USD 4.7 billion by 2027, at a compound annual growth rate (CAGR) of 13.0% during the forecast period.The Key players Oracle Corporation (US), General Electric (US), Lufthansa Technik (Germany), SAP (Germany), and IBM (US).
- Published: September 2022
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
